Menu

Obesity Research Pioneer Dies

Douglas Coleman, the biochemist and geneticist whose early experiments led to the discovery of leptin, has passed away at age 82.

Apr 28, 2014
Rina Shaikh-Lesko

JACKSON LABORATORYBiochemist and geneticist Douglas Coleman, who helped uncover the role of leptin in obesity, died last week (April 16) from complications of basal cell carcinoma. He was 82.

During the late 1960s and early 1970s, while working at the Jackson Laboratory in Bar Harbor, Maine, Coleman identified a blood-borne “satiety factor” linked to obesity and diabetes in mice. At the time, most researchers thought obesity was strictly behavior-related, leading many to doubt his results. By the 1990s, however, Jeffrey Friedman from the Rockefeller University in New York followed up on Coleman’s findings and identified the hormone leptin and its associated gene. Coleman and Friedman shared a Lasker Prize for this work in 2010, The New York Times reported. That same year, Thomson Reuters named Coleman a contender for the Nobel Prize in physiology or medicine, although he did not win.

“Doug was a scientist’s scientist and a good friend,” Friedman said in a statement.

Coleman was born in Stratford, Ontario, in 1931. He earned an undergraduate degree in chemistry from McMaster University in Hamilton, Ontario, and a PhD in biochemistry from the University of Wisconsin, Madison. In 1958, Coleman began working at the Jackson Lab, where he spent the remainder of his career. After retiring from research, he converted a plot of land he owned in Lamoine, Maine, into a nature preserve.

He is survived by two sons and one grandson.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.